JP2013514356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013514356A5 JP2013514356A5 JP2012544596A JP2012544596A JP2013514356A5 JP 2013514356 A5 JP2013514356 A5 JP 2013514356A5 JP 2012544596 A JP2012544596 A JP 2012544596A JP 2012544596 A JP2012544596 A JP 2012544596A JP 2013514356 A5 JP2013514356 A5 JP 2013514356A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- methyl
- amino
- cyclohexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 4-dihydro-2H-benzo [b] [1,4] dioxepinyl Chemical group 0.000 claims 67
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 48
- 229910052739 hydrogen Inorganic materials 0.000 claims 48
- 239000001257 hydrogen Substances 0.000 claims 48
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 46
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 37
- 125000001424 substituent group Chemical group 0.000 claims 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 34
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 27
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 25
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 23
- 125000005843 halogen group Chemical group 0.000 claims 19
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000004076 pyridyl group Chemical group 0.000 claims 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 9
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 9
- 125000003226 pyrazolyl group Chemical group 0.000 claims 9
- 125000001041 indolyl group Chemical group 0.000 claims 8
- 150000001408 amides Chemical class 0.000 claims 7
- 125000005059 halophenyl group Chemical group 0.000 claims 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 6
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 5
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000001207 fluorophenyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims 4
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- 102000015617 Janus Kinases Human genes 0.000 claims 3
- 108010024121 Janus Kinases Proteins 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims 3
- 125000006301 indolyl methyl group Chemical group 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 claims 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- OYQDGNSVNFKSAP-JOCQHMNTSA-N C([C@H]1CC[C@@H](CC1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)NC1=CC=NN1 Chemical compound C([C@H]1CC[C@@H](CC1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)NC1=CC=NN1 OYQDGNSVNFKSAP-JOCQHMNTSA-N 0.000 claims 1
- IXSDUBAEMRHZJB-SGNKCFNYSA-N C[C@H](CC1)CC[C@@H]1N(CC1=CC=C2NC(C)=CC2=C1)C1=NC(C)=NC2=C1C=CN2 Chemical compound C[C@H](CC1)CC[C@@H]1N(CC1=CC=C2NC(C)=CC2=C1)C1=NC(C)=NC2=C1C=CN2 IXSDUBAEMRHZJB-SGNKCFNYSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28792409P | 2009-12-18 | 2009-12-18 | |
| US61/287,924 | 2009-12-18 | ||
| PCT/US2010/059046 WO2011075334A1 (en) | 2009-12-18 | 2010-12-06 | Pyrrolo[2,3-d]pyrimidine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013514356A JP2013514356A (ja) | 2013-04-25 |
| JP2013514356A5 true JP2013514356A5 (enExample) | 2014-01-09 |
| JP5739446B2 JP5739446B2 (ja) | 2015-06-24 |
Family
ID=43618844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012544596A Expired - Fee Related JP5739446B2 (ja) | 2009-12-18 | 2010-12-06 | ピロロ［２，３−ｄ］ピリミジン化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8372854B2 (enExample) |
| EP (1) | EP2513114B1 (enExample) |
| JP (1) | JP5739446B2 (enExample) |
| CA (1) | CA2782720A1 (enExample) |
| ES (1) | ES2461967T3 (enExample) |
| WO (1) | WO2011075334A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1966202E (pt) | 2005-12-13 | 2012-01-03 | Incyte Corp | Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase |
| MX354212B (es) | 2010-03-10 | 2018-02-19 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| US9216999B2 (en) | 2011-08-12 | 2015-12-22 | Nissan Chemical Industries, Ltd. | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors |
| US9394282B2 (en) | 2011-09-22 | 2016-07-19 | Merck Sharp & Dohme Corp. | Pyrazole carboxamides as Janus kinase inhibitors |
| US8993756B2 (en) | 2011-12-06 | 2015-03-31 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| JO3384B1 (ar) * | 2012-07-17 | 2019-03-13 | Glaxosmithkline Ip No 2 Ltd | مركبات إندول كربونيتريل في صورة معدلات لمستقبل أندروجين انتقائية |
| NZ708157A (en) | 2012-11-15 | 2019-07-26 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| US20160123982A1 (en) | 2013-02-04 | 2016-05-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| ES2755130T3 (es) | 2013-02-08 | 2020-04-21 | Nissan Chemical Corp | Compuesto de pirrolopiridina tricíclico, e inhibidor de JAK |
| SI3290421T1 (sl) | 2013-02-22 | 2019-03-29 | Pfizer Inc. | Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK) |
| MX394928B (es) | 2013-08-07 | 2025-03-24 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| EP2924026A1 (en) * | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| MX374105B (es) | 2014-05-14 | 2025-03-05 | Nissan Chemical Ind Ltd | Compuestos azatricíclicos como inhibidores de tirosinas quinasas (jak) y el uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y alérgicas. |
| WO2016024185A1 (en) * | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| TWI679205B (zh) | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
| CN108699072B (zh) * | 2016-02-16 | 2021-02-26 | 硕腾服务有限责任公司 | 用于制备7h-吡咯并[2,3-d]嘧啶化合物的方法 |
| CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
| TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
| CN107365312B (zh) * | 2016-05-13 | 2021-10-01 | 瑞博(杭州)医药科技有限公司 | 一种制备Oclacitinib的新方法 |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| WO2020155931A1 (zh) | 2019-01-30 | 2020-08-06 | 格格巫（珠海）生物科技有限公司 | 一种jak抑制剂及其制备方法 |
| WO2020232470A1 (en) | 2019-05-13 | 2020-11-19 | Boragen, Inc. | Chemical compounds |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN114605420B (zh) * | 2022-04-25 | 2024-07-12 | 江苏慧聚药业股份有限公司 | 马来酸奥拉替尼的合成方法 |
| CN118255769A (zh) * | 2022-12-28 | 2024-06-28 | 格格巫（珠海）生物科技有限公司 | 一种立体异构体的制备方法及中间体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| EP1087970B1 (en) * | 1998-06-19 | 2004-04-28 | Pfizer Products Inc. | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| CN1195755C (zh) | 1999-12-10 | 2005-04-06 | 辉瑞产品公司 | 吡咯并[2,3－d]嘧啶化合物 |
| SK17342002A3 (sk) * | 2000-06-26 | 2004-06-08 | Pfizer Products Inc. | Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| RS20050380A (sr) | 2002-11-21 | 2007-11-15 | Pfizer Products Inc., | Derivati 3-aminopiperidina i postupci njihove proizvodnje |
| MX286273B (es) | 2005-06-08 | 2011-05-04 | Rigel Pharmaceuticals Inc | Composiciones y metodos para inhibicion de la via jak. |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| ATE540952T1 (de) | 2005-07-29 | 2012-01-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese |
| CN101801971A (zh) * | 2005-09-30 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作janus激酶抑制剂的脱氮嘌呤 |
| MY167260A (en) | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| CA2642229C (en) | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| CA2674875A1 (en) * | 2007-01-23 | 2008-07-31 | Palau Pharma, S.A. | Purine derivatives |
| BRPI0917459B1 (pt) * | 2008-08-20 | 2017-09-12 | Zoetis Services Llc | N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide |
| CA2776028C (en) * | 2009-10-15 | 2015-12-01 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
-
2010
- 2010-12-06 EP EP10807506.0A patent/EP2513114B1/en not_active Not-in-force
- 2010-12-06 JP JP2012544596A patent/JP5739446B2/ja not_active Expired - Fee Related
- 2010-12-06 WO PCT/US2010/059046 patent/WO2011075334A1/en not_active Ceased
- 2010-12-06 CA CA2782720A patent/CA2782720A1/en not_active Abandoned
- 2010-12-06 ES ES10807506.0T patent/ES2461967T3/es active Active
- 2010-12-10 US US12/964,841 patent/US8372854B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013514356A5 (enExample) | ||
| US8513242B2 (en) | Pyrimidine compounds and methods of making and using same | |
| ME01507B (me) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
| AU2003264076B2 (en) | Pyrimidine derivatives and their use as CB2 modulators | |
| ES2439894T3 (es) | Derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimioquina | |
| JP2011252024A5 (enExample) | ||
| JP2013510876A5 (enExample) | ||
| JP2012515209A5 (enExample) | ||
| RU2018137194A (ru) | Ингибиторы бромдомена | |
| ZA200606880B (en) | Diaminopyrimidines as P2X3 and P2X2/3 antagonists | |
| JP2016510035A5 (enExample) | ||
| ES2543904T9 (es) | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus | |
| JP2017522346A5 (enExample) | ||
| JP2011517458A5 (enExample) | ||
| RU2011134052A (ru) | Новые бензолсульфонамиды в качестве блокаторов кальциевых каналов | |
| JP2010502716A5 (enExample) | ||
| JP2010510319A5 (enExample) | ||
| JP2011518836A5 (enExample) | ||
| JP2012515724A5 (enExample) | ||
| RU2011149360A (ru) | Замещенные фенилмочевины и фениламиды в качестве лигандов ваниллоидных рецепторов | |
| RU2015143191A (ru) | Дигидропирролопиридиновые ингибиторы бромодоменов | |
| JP2011518158A5 (enExample) | ||
| JP2016519685A5 (enExample) | ||
| WO2013040044A1 (en) | Aminopyrimidine derivatives for use as modulators of kinase activity | |
| CN1950351A (zh) | 适用作h3配体的3－或4－单取代酚及苯硫酚衍生物 |